To the attention of Contract Research Organisations
In the context of the COVID-19 pandemic, the NAMMDR hereby advises on its plan to prioritise assessment of clinical trials with medicines for the treatment of COVID-19 infection; depending on the number of applications and the phase of the trial (Phase III trials shall be considered a priority), the deadline for completion of assessment is expected to not exceed 7 days at most.
Please note that, for this type of trials as well, the NAMMDR encourages use of EU coordinated assessment through the VHP procedure; in such cases, the procedure timetable is established in agreement with the other Member States.